Complications of hormonal therapy (ADT - androgen deprivation therapy) and the movement system in patients with prostate cancer
PDF (Język Polski)

Keywords

polski

How to Cite

Korczak, J. (2020). Complications of hormonal therapy (ADT - androgen deprivation therapy) and the movement system in patients with prostate cancer. Letters in Oncology Science, 17(1), 1-6. https://doi.org/10.21641/los.2020.17.1.156

Abstract

Androgen Deprivation Therapy is the basis for treatment of advanced prostate cancer. The beneficial influence of ADT on treatment results has been documented. In the clinical practice different complications, related to ADT use, have been observed, among which the musculoskeletal evolve dynamically and tend to deteriorate the patient’s quality of life and daily activity. To prevent or minimize the dynamics of development of these complications it is suggested vitamin D and calcium supplementation, and above all to perform physical exercises and modification of dietary habits. In the current study, the influence of ADT on the skeletal and muscular systems, methods of its diagnosis and prophylaxis has been shown.

https://doi.org/10.21641/los.2020.17.1.156
PDF (Język Polski)

References

1. Epidemiology of prostate cancer in Europe [Internet]. European Commission, 2015. Available from: https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancer-europe
2. Grossmann M, Zajac JD. Management of Side Effects of Androgen Deprivation Therapy. Endocrinol Metab Clin North Am., 2011;40:655-671
3. Mitsuzuka K, Arai Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int J Urol, 2018;25:45-53
4. Lorenc R, Głuszko P, Franek E, Jabłoński M, Jaworski M, et al. Zalecenia postępowania diagnostycznego i leczniczego w osteoporozie w Polsce. Aktualizacja 2017. Endokrynologia Polska, Tom, Vol. 68; Suplement A.
5. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89
6. Holmes-Walker DJ, Woo H, Gurney H, Do VT, Chipps DR. Maintaining bone health in patients with prostate cancer. Med J Aust 2006; 184: 76-179
7. Greenspan SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 2008; 93: 2-7
8. Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 2006; 175: 1679-1683
9. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-6417
10. Owen PJ, Daly RM, Livingston PM Fraser SF. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer and Prostatic Dis, 2017;20:137–145
11. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
12. https://www.sheffield.ac.uk/FRAX/tool.aspx?lang=po
13. Wojtukiewicz M. Tokasiuk P, Fijuth J, Zaucha R, Wysocki P, Kowalski D. Stosowanie kwasu zoledronowego w celu zapobiegania zdarzeniom kostnym u chorych na nowotwory złośliwe z przerzutami do kości - stanowisko ekspertów. Personalized Oncology. 2017;1(1)5-23
14. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. ESMO Guidelines Working Group. Ann Oncol. 2014;25:124-37
15. Almeida M, Laurent MR, Dubois V, Claessens F, O'Brien CA, Bouillon R et al. Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev. 2017;97(1): 135–187
16. Morawin B. Rola testosteronu w regeneracji mięśni szkieletowych po wysiłku fizycznym. Rocznik Lubuski. 2014;40,cz 2
17. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ Ke Ch. Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2012;30(26): 3271–3276
18. Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging. 2018;22(10):1148-1161
19. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People, Age Ageing, 2010;39(4):412-23.
20. Christensen JF, Jones LW, Andersen JL, Daugaard G, Rorth M, Hojman P. Muscle dysfunction in cancer patients. AnnOncol 2014;25:947–958
21. Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol. 2018; 29:1–9
22. Krzymińska-Siemaszko R. Wskaźniki niskiej masy mięśniowej w definiowaniu sarkopenii. Rozprawa doktorska. Poznań: Uniwersytet Medyczny im. K. Marcinkowskiego w Poznaniu, Katedra i Klinika Medycyny Paliatywnej; 2014
23. Soyupek F, Soyupek S, Perk H, Ozorak A. Androgen deprivation therapy for prostate cancer: effects on hand function. Urol Oncol 2008;26: 141–146
24. Reis C, Liberman S, Pompeo AC, Srougi M, Halpern A, Jacob Filho W Body composition alterarions, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy. Clinics (Sao Paulo) 2009;64: 781–784
25. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf ) 2011; 74: 377–383
26. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 2007; 25:4396–4404
27. Hanson ED1, Sheaff AK, Sood S, Ma L, Francis JD, Goldberg AP et al. Strength training induces muscle hypertrophy and functional gains in black prostate cancer patients despite androgen deprivation therapy. J Gerontol A Biol Sci Med Sci 2012;68: 490–498
28. Dicato MA, Van Cutsem E. Side Effects of Medical Cancer Therapy Prevention and Treatment 2nd ed. Springer; 2018
29. Galvão DA, Taaffe DR, Spry N, Cormie P, Joseph D, Chambers SK et al. Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases. Med. Sci. Sports Exer, 2018;50(3);393–399
30. Buffart LM, Galvão DA, Brug J, Chinapaw MJM, Newton RU. Evidence-based physical activity guidelines for cancer survivors: Current guidelines, knowledge gaps and future research directions. Asian Journal of Andrology. 2012;14:204–221
31. Storer TW, Miciek R, Travison T. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl, 2012;14(2):204–221
32. Focht BC, Lucas AR. Effects of a Group-Mediated Exercise and Dietary Intervention in the Treatment of Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Results From the IDEA-P Trial. Ann. Behav. Med. 2018; 52:412–428
Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.